6MKD Stock Overview
Operates as a healthcare company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$85.60 |
| 52 Week High | US$121.20 |
| 52 Week Low | US$80.10 |
| Beta | 0.36 |
| 1 Month Change | -1.50% |
| 3 Month Change | n/a |
| 1 Year Change | -22.88% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6MKD | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | -1.5% |
| 1Y | -22.9% | 8.0% | 7.2% |
Return vs Industry: 6MKD underperformed the UK Pharmaceuticals industry which returned 5.8% over the past year.
Return vs Market: 6MKD underperformed the UK Market which returned 6.8% over the past year.
Price Volatility
| 6MKD volatility | |
|---|---|
| 6MKD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 8.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.1% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 6MKD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 6MKD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 74,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Merck & Co., Inc. Fundamentals Summary
| 6MKD fundamental statistics | |
|---|---|
| Market cap | €216.71b |
| Earnings (TTM) | €15.73b |
| Revenue (TTM) | €58.97b |
13.8x
P/E Ratio3.7x
P/S RatioIs 6MKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6MKD income statement (TTM) | |
|---|---|
| Revenue | US$64.17b |
| Cost of Revenue | US$14.70b |
| Gross Profit | US$49.47b |
| Other Expenses | US$32.35b |
| Earnings | US$17.12b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | 6.78 |
| Gross Margin | 77.09% |
| Net Profit Margin | 26.68% |
| Debt/Equity Ratio | 80.0% |
How did 6MKD perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield46%
Payout RatioDoes 6MKD pay a reliable dividends?
See 6MKD dividend history and benchmarks| Merck dividend dates | |
|---|---|
| Ex Dividend Date | Mar 17 2025 |
| Dividend Pay Date | Apr 07 2025 |
| Days until Ex dividend | 3 days |
| Days until Dividend pay date | 24 days |
Does 6MKD pay a reliable dividends?
See 6MKD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 08:09 |
| End of Day Share Price | 2025/03/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merck & Co., Inc. is covered by 53 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Fabrizio Spagna | Axia Financial Research |
| Ishan Majumdar | Baptista Research |